Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
rAAV2/5-PBGD · 1 trial · 1 indication
To assess the safety and determine the maximum therapeutic safe dose of the investigational gene therapy (GT) product rAAV2/5-PBGD for the treatment of AIP, registering and evaluating the occurrence of Adverse Events and/or Serious Adverse Events at the dose identified will be performed
| Arm | Type | Description |
|---|---|---|
| Cohort A | EXPERIMENTAL | rAAV2/5-PBGD vector dosage 1 |
| Cohort B | EXPERIMENTAL | rAAV2/5-PBGD vector dosage 2 |
| Cohort C | EXPERIMENTAL | rAAV2/5-PBGD vector dosage 3 |
| Cohort D | EXPERIMENTAL | rAAV2/5-PBGD vector dosage 4 |
| Name | Type | Description |
|---|---|---|
| rAAV2/5-PBGD vector dosage 1 | GENETIC | Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1. |
| rAAV2/5-PBGD vector dosage 2 | GENETIC | Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1. |
| rAAV2/5-PBGD vector dosage 3 | GENETIC | Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1. |
| rAAV2/5-PBGD vector dosage 4 | GENETIC | Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1. |
Inclusion Criteria: * Patient's written Informed Consent * Age between 18 and 64 years, inclusively. * Patients with confirmed diagnosis of Acute Intermittent Porphyria(AIP), as confirmed by clinical, biochemical data and genetic confirmation of porphobilinogen deaminase (PBGD) gene mutation. The p...
rAAV2/5-PBGD is an investigational gene therapy developed by uniQure N.V. for acute intermittent porphyria. It is a recombinant adeno-associated viral vector designed to deliver a gene to patients with this rare inherited metabolic disorder. It has been studied in a single Phase 1 clinical trial conducted in Spain.
rAAV2/5-PBGD is being studied as a gene therapy treatment for acute intermittent porphyria, a rare inherited disorder of heme metabolism. The approach aims to address the underlying genetic defect rather than manage symptoms alone. The only clinical trial of rAAV2/5-PBGD enrolled adults 18 years and older with the condition.
rAAV2/5-PBGD is developed by uniQure N.V., a gene therapy company whose shares trade under the ticker QURE. uniQure sponsored the Phase 1 clinical trial of the vector for acute intermittent porphyria. The program is part of the company's gene therapy portfolio in rare disease.
rAAV2/5-PBGD is in Phase 1 development. Its single clinical trial, NCT02082860, has been completed. The study was a controlled Phase 1 gene therapy trial with 8 enrolled participants, conducted in Spain in adults aged 18 years and older. rAAV2/5-PBGD is investigational and has not been approved by the FDA.
rAAV2/5-PBGD has been evaluated in one clinical trial, NCT02082860, titled a Phase I gene therapy clinical trial using the vector rAAV2/5-PBGD for the treatment of acute intermittent porphyria. The trial is completed, enrolled 8 participants, was controlled but not randomized or double blind, and took place in Spain.